MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-12-2025
Rockwell Medical Total Assets 2011-2025 | RMTI
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets Rockwell Medical
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 52.2 M | 46.6 M | 48.6 M | 77.7 M | 44.3 M | 52.6 M | 58.8 M | 83.2 M | 87.8 M | 98 M | 36.4 M | 17 M | 31.9 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 98 M | 17 M | 56.5 M |
Quarterly Total Assets Rockwell Medical
| 2025-Q3 | 2025-Q2 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 57.5 M | 52.6 M | 59.2 M | 57.1 M | 53 M | 50.7 M | 52.2 M | 52.6 M | 38 M | 40.5 M | 46.6 M | 54.2 M | 59.1 M | 37.4 M | 48.6 M | 58.7 M | 63.7 M | 69.4 M | 77.7 M | 77.7 M | 77.7 M | 77.7 M | 44.3 M | 44.3 M | 44.3 M | 44.3 M | 52.6 M | 52.6 M | 52.6 M | 52.6 M | 58.8 M | 58.8 M | 58.8 M | 58.8 M | 83.2 M | 83.2 M | 83.2 M | 83.2 M | 87.8 M | 87.8 M | 87.8 M | 87.8 M | 98 M | 98 M | 98 M | 98 M | 36.4 M | 36.4 M | 36.4 M | 36.4 M | 17 M | 17 M | 17 M | 17 M | 31.9 M | 31.9 M | 31.9 M | 31.9 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 98 M | 17 M | 56.9 M |
Total Assets of other stocks in the Drug manufacturers industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Alimera Sciences
ALIM
|
154 M | - | - | $ 142 M |  USA |
 |
Aerie Pharmaceuticals
AERI
|
431 M | - | - | $ 754 M | USA |
 |
Canopy Growth Corporation
CGC
|
918 M | $ 1.21 | 1.68 % | $ 130 M |  Canada |
 |
AcelRx Pharmaceuticals
ACRX
|
18.2 M | - | 7.5 % | $ 6.35 M | USA |
 |
Cronos Group
CRON
|
1.93 B | $ 2.67 | 0.19 % | $ 1.39 B | Canada |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
10.9 M | - | 0.86 % | $ 117 M | USA |
 |
Catalent
CTLT
|
9.75 B | - | - | $ 11.5 B | USA |
 |
Agile Therapeutics
AGRX
|
10.3 M | - | 10.11 % | $ 58.2 M | USA |
 |
DURECT Corporation
DRRX
|
45.2 M | - | - | $ 50.1 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
406 M | - | -39.89 % | $ 27.7 M | USA |
 |
Aurora Cannabis
ACB
|
853 M | $ 4.35 | -3.12 % | $ 86.3 M | Canada |
 |
Endo International plc
ENDP
|
5.14 B | - | - | $ 28.9 M |  Irlanda |
 |
Zomedica Corp.
ZOM
|
253 M | - | -0.21 % | $ 98 M | USA |
 |
Evoke Pharma
EVOK
|
7.07 M | - | - | $ 36.6 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
1.46 B | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
681 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Zynerba Pharmaceuticals
ZYNE
|
55.5 M | - | - | $ 55.5 M | USA |
 |
Emergent BioSolutions
EBS
|
1.82 B | $ 12.29 | -1.09 % | $ 629 M | USA |
 |
Athenex
ATNX
|
204 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
164 M | $ 21.57 | -0.12 % | $ 2.05 B |  France |
 |
Evolus
EOLS
|
233 M | $ 6.66 | -3.55 % | $ 413 M | USA |
 |
Harrow Health
HROW
|
312 M | $ 50.7 | 1.22 % | $ 1.65 B | USA |
 |
China Pharma Holdings
CPHI
|
14.9 M | $ 1.27 | -1.32 % | $ 22.2 M |  China |
 |
OrganiGram Holdings
OGI
|
408 M | $ 1.7 | -5.31 % | $ 402 M | Canada |
 |
Neoleukin Therapeutics
NLTX
|
223 M | - | - | $ 193 M | Canada |
 |
Organogenesis Holdings
ORGO
|
498 M | $ 5.19 | -1.71 % | $ 683 M | USA |
 |
Bausch Health Companies
BHC
|
27.4 B | $ 7.16 | -0.56 % | $ 2.61 B | Canada |
 |
Lannett Company
LCI
|
484 M | - | 1.15 % | $ 7.11 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
13.7 M | $ 3.66 | 0.83 % | $ 4.54 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
75.6 M | $ 4.01 | -2.55 % | $ 56.4 M | USA |
 |
Pacira BioSciences
PCRX
|
1.55 B | $ 26.17 | -1.3 % | $ 1.21 B | USA |
 |
Sundial Growers
SNDL
|
1.35 B | $ 1.71 | -1.16 % | $ 3.37 M | Canada |
 |
PetIQ
PETQ
|
868 M | - | 1.64 % | $ 400 M | USA |
 |
Jupiter Wellness
JUPW
|
7.34 M | - | - | $ 33.6 M | USA |
 |
Veru
VERU
|
60.4 M | $ 2.22 | -7.71 % | $ 299 M | USA |
 |
Perrigo Company plc
PRGO
|
9.65 B | $ 13.94 | 0.87 % | $ 1.92 B | USA |
 |
ProPhase Labs
PRPH
|
87.6 M | $ 0.45 | -14.17 % | $ 7.13 M | USA |
 |
Radius Health
RDUS
|
182 M | - | - | $ 1.42 B | USA |
 |
cbdMD
YCBD
|
10.6 M | $ 1.43 | -15.88 % | $ 6.17 M | USA |
 |
Recro Pharma
REPH
|
153 M | - | -4.76 % | $ 65.3 M | USA |
 |
Relmada Therapeutics
RLMD
|
97.6 M | $ 4.43 | -1.77 % | $ 133 M | USA |
 |
OptiNose
OPTN
|
108 M | - | - | $ 1.08 B | USA |
 |
Assertio Holdings
ASRT
|
286 M | $ 9.56 | -3.82 % | $ 679 M | USA |
 |
PLx Pharma
PLXP
|
76.6 M | - | -27.8 % | $ 2.56 M | USA |
 |
Solid Biosciences
SLDB
|
189 M | $ 5.63 | -3.68 % | $ 230 M | USA |
 |
SCYNEXIS
SCYX
|
128 M | $ 0.63 | 6.75 % | $ 30.1 M | USA |
 |
Tricida
TCDA
|
169 M | - | - | $ 3.25 M | USA |
 |
Tilray
TLRY
|
4.31 B | $ 9.32 | -2.87 % | $ 5.76 B | Canada |
 |
TherapeuticsMD
TXMD
|
43.3 M | $ 1.68 | -3.43 % | $ 17.5 M | USA |